🇺🇸 insulin degludec + liraglutide in United States

58 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Diarrhoea — 9 reports (15.52%)
  2. Acute Kidney Injury — 7 reports (12.07%)
  3. Nausea — 7 reports (12.07%)
  4. Drug Ineffective — 6 reports (10.34%)
  5. Abdominal Distension — 5 reports (8.62%)
  6. Dyspnoea — 5 reports (8.62%)
  7. Gastrooesophageal Reflux Disease — 5 reports (8.62%)
  8. Hypertension — 5 reports (8.62%)
  9. Hypoglycaemia — 5 reports (8.62%)
  10. Abdominal Pain — 4 reports (6.9%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is insulin degludec + liraglutide approved in United States?

insulin degludec + liraglutide does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for insulin degludec + liraglutide in United States?

Hospital Universitario San Ignacio is the originator. The local marketing authorisation holder may differ — check the official source linked above.